Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toward Individualized Therapy in Acute Myeloid Leukemia
Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortés, et al.
JAMA Oncology (2015) Vol. 1, Iss. 6, pp. 820-820
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Acute myeloid leukaemia
Nicholas J. Short, Michael Rytting, Jorge E. Cortés
The Lancet (2018) Vol. 392, Iss. 10147, pp. 593-606
Open Access | Times Cited: 667
Acute myeloid leukemia: current progress and future directions
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 546
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, et al.
Cancer (2021) Vol. 127, Iss. 12, pp. 2049-2061
Open Access | Times Cited: 181
Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML
Mohammed Dany, Salih Gencer, Rose Nganga, et al.
Blood (2016) Vol. 128, Iss. 15, pp. 1944-1958
Open Access | Times Cited: 173
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, et al.
Cancer (2021) Vol. 127, Iss. 8, pp. 1186-1207
Open Access | Times Cited: 129
Acute myeloid leukemia—Major progress over four decades and glimpses into the future
Hagop Kantarjian
American Journal of Hematology (2015) Vol. 91, Iss. 1, pp. 131-145
Open Access | Times Cited: 141
Frontline treatment of acute myeloid leukemia in adults
Gevorg Tamamyan, Tapan M. Kadia, Farhad Ravandi, et al.
Critical Reviews in Oncology/Hematology (2016) Vol. 110, pp. 20-34
Open Access | Times Cited: 130
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
Dang Wu, Wanyan Wang, Wuyan Chen, et al.
Haematologica (2018) Vol. 103, Iss. 9, pp. 1472-1483
Open Access | Times Cited: 82
Microfluidic cell sorting by stiffness to examine heterogenic responses of cancer cells to chemotherapy
Muhymin Islam, Roman Mezencev, Brynn McFarland, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 2
Open Access | Times Cited: 64
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Ivana Gojo, Jan H. Beumer, Keith W. Pratz, et al.
Clinical Cancer Research (2016) Vol. 23, Iss. 3, pp. 697-706
Open Access | Times Cited: 63
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
Brittany Knick Ragon, Olatoyosi Odenike, Maria R. Baer, et al.
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 19, Iss. 7, pp. 431-440.e13
Open Access | Times Cited: 59
A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia
Anuradha Kirtonia, Gouri Pandya, Gautam Sethi, et al.
Journal of Molecular Medicine (2020) Vol. 98, Iss. 8, pp. 1069-1091
Closed Access | Times Cited: 57
Toward the potential cure of leukemias in the next decade
Hagop M. Kantarjian, Michael J. Keating, Emil J. Freireich
Cancer (2018) Vol. 124, Iss. 22, pp. 4301-4313
Open Access | Times Cited: 48
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
Hagop M. Kantarjian, Nicholas J. Short, Amir T. Fathi, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 9, pp. 580-597
Closed Access | Times Cited: 41
Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies
Ekta Pardhi, Rati Yadav, Akash Chaurasiya, et al.
Life Sciences (2023) Vol. 325, pp. 121771-121771
Closed Access | Times Cited: 16
Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia
Yiling Wang, Yan Yang, Xi Zheng, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges
Ying Chen, Jishi Wang, Fengqi Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
Curcumin in treatment of hematological cancers: Promises and challenges
Maliheh Entezari, Armita Tayari, Mahshid Deldar Abad Paskeh, et al.
Journal of Traditional and Complementary Medicine (2024) Vol. 14, Iss. 2, pp. 121-134
Open Access | Times Cited: 6
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia
Brittany Knick Ragon, Naval Daver, Guillermo Garcia‐Manero, et al.
American Journal of Hematology (2017) Vol. 92, Iss. 9, pp. 845-850
Open Access | Times Cited: 45
Structural insights into amyloid structures of the C-terminal region of nucleophosmin 1 in type A mutation of acute myeloid leukemia
Concetta Di Natale, Sara La Manna, Anna Maria Malfitano, et al.
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics (2019) Vol. 1867, Iss. 6, pp. 637-644
Closed Access | Times Cited: 42
The cure of leukemia through the optimist's prism
Hagop M. Kantarjian, Nitin Jain, Guillermo Garcia‐Manero, et al.
Cancer (2021) Vol. 128, Iss. 2, pp. 240-259
Open Access | Times Cited: 29
MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6
Xiangdong Lu, Jingjing Ma, Jiahui Chu, et al.
Cellular Physiology and Biochemistry (2017) Vol. 44, Iss. 6, pp. 2346-2356
Open Access | Times Cited: 37
Topoisomerase II inhibitors in AML: past, present, and future
Minas P. Economides, Deborah McCue, Gautam Borthakur, et al.
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 13, pp. 1637-1644
Closed Access | Times Cited: 34
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
Jayastu Senapati, Mahran Shoukier, Guillermo Garcia‐Manero, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 574-582
Open Access | Times Cited: 19
Hypomethylation of GCNT2 isoform A correlates with transcriptional expression and is associated with poor survival in acute myeloid leukemia
Dehong Wu, Hao Qiu, Jing Xu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top